Добірка наукової літератури з теми "Chaînes légères libres kappa"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Chaînes légères libres kappa".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Статті в журналах з теми "Chaînes légères libres kappa":
Micoud, Eléonore, Morgane Gossez, Françoise Poitevin, Christophe Malcus, Guillaume Monneret, and Marine Godignon. "Apport du dosage des chaînes légères libres kappa et lambda dans le diagnostic de la sclérose en plaques." Revue Francophone des Laboratoires 2021, no. 531 (April 2021): 58–64. http://dx.doi.org/10.1016/s1773-035x(21)00108-8.
Bertho, Pierre Olivier, Edouard Le Carpentier, Guillaume Herbreteau, Anne Hay-Lombardie, and Edith Bigot-Corbel. "Dosage des chaînes légères libres Kappa dans le LCS et apport de l’index Kappa selon la présence ou non de bandes oligoclonales d’IgG." Revue Neurologique 177 (April 2021): S130. http://dx.doi.org/10.1016/j.neurol.2021.02.379.
Guillermin, Y., A. S. Michallet, C. Lombard, C. Chapuis Cellier, Q. Reynaud, A. Chuilon, G. Salles, I. Durieu, and J. C. Lega. "Le ration kappa/lambda des chaînes légères libres sériques est un biomarqueur prédictif de la rechute dans la thrombopénie auto-immune idiopathique." La Revue de Médecine Interne 36 (June 2015): A52. http://dx.doi.org/10.1016/j.revmed.2015.03.286.
Wang, Michael, Stefan Jevtic, Ryan Rebello, and Adam Komorowski. "Lenalidomide-Associated Progressive Multifocal Leukoencephalopathy." Canadian Journal of General Internal Medicine 18, no. 2 (June 5, 2023): 12–17. http://dx.doi.org/10.22374/cjgim.v18i2.687.
Martellosio, J. P., A. Barra, F. Roy-Peaud, O. Souchaud-Debouverie, C. Lateur, J. M. Gombert, P. Roblot, and M. Puyade. "Étude du comportement du rapport kappa/lambda des chaînes légères libres sériques (test Freelite) et du rapport Ig kappa/Ig lambda (test Hevylite) chez 32 patients adultes atteints de PTI (purpura thrombopénique immunologique)." La Revue de Médecine Interne 39 (December 2018): A152—A153. http://dx.doi.org/10.1016/j.revmed.2018.10.102.
Martellosio, J. P., X. Leleu, P. Roblot, M. Martin, and M. Puyade. "Dosage des chaînes légères libres : indications et méthodes." La Revue de Médecine Interne 40, no. 5 (May 2019): 297–305. http://dx.doi.org/10.1016/j.revmed.2019.01.005.
Emile, Carole. "Dosage des chaînes légères libres dans les gammapathies monoclonales." Option/Bio 25, no. 508-509 (May 2014): 19–20. http://dx.doi.org/10.1016/s0992-5945(14)71773-8.
Chevailler, Alain, Bach-Nga Pham, and Marie-Christine Bene. "Du bon usage des dosages des chaînes légères libres d'immunoglobulines." Revue Francophone des Laboratoires 2007, no. 394 (July 2007): 21. http://dx.doi.org/10.1016/s1773-035x(07)80299-1.
Foray, V., and C. Chapuis-Cellier. "Apport du dosage des chaînes légères libres d'immunoglobulines dans le diagnostic et le suivi des gammapathies monoclonales à chaînes légères." Immuno-analyse & Biologie Spécialisée 20, no. 6 (December 2005): 385–93. http://dx.doi.org/10.1016/j.immbio.2005.10.004.
Émile, Carole. "Apport du dosage des chaînes légères libres sériques en hématologie clinique." Option/Bio 23, no. 470 (April 2012): 20–21. http://dx.doi.org/10.1016/s0992-5945(12)71239-4.
Дисертації з теми "Chaînes légères libres kappa":
Levraut, Michaël. "Évaluations des chaînes légères libres sériques et intrathécales comme biomarqueur diagnostique et pronostique dans la sclérose en plaques." Electronic Thesis or Diss., Université Côte d'Azur, 2023. http://www.theses.fr/2023COAZ6055.
Multiple sclerosis (MS) is one of the most common central nervous system (CNS) inflammatory and demyelinating disease worldwide, and is the main cause of non-traumatic disability in young adults. Multiple sclerosis prognosis improved during the past 20-years because of treatments development and efficacy and the successive revisions of MS diagnostic criteria that allow to diagnose MS sooner, thanks to their high sensitivity. Nonetheless, the gain in sensitivity in MS diagnostic criteria leads to a loss of specificity increasing the risk of misdiagnosis. We lack sensitive and specific biomarkers that could help clinicians to diagnose MS accurately. Given the pathological processes leading to CNS inflammation in MS, we aimed to evaluate the diagnostic performances of four cytokines implicated in different inflammatory mechanisms (IL-1β, soluble IL-2 receptor (sIL-2R), IL-6, et IL-10) and kappa free light chains (kappa FLC). The performances of all these biomarkers were compared to those of oligoclonal bands (OCB).In Nice University Hospital MS tertiary center, we set up a monocentric prospective cohort (CyBIRD cohort, NCT05056740) that included all adult patients referred for a clinical or MRI suspicion of MS. Of the 176 included patients, both the kappa FLC index and the kappa FLC intrathecal fraction (IF) were able to differentiate MS and non-MS patients (AUC of 0.90 and 0.89 respectively). Cerebrospinal fluid (CSF) IL-6 and sIL-2R concentrations favored non-MS inflammatory CNS disorders (AUC of 0.87 and 0.77 respectively). According to our optimal threshold, a positive kappa FLC index performed better than OB for MS diagnosis (AUC 0.82 vs 0.74).To confirm our results, we conducted, on behalf of the French MS Society, a multicenter retrospective study where 1,621 patients were included. Based on this cohort, the kappa FLC index (AUC 0.94) and the kappa FLC IF (0.94) had similar diagnostic performances (p=.123), higher than the CSF kappa FLC concentration ones (AUC 0.91, p<.0001). A positive kappa FLC index (threshold of 8.9) was more sensitive (88% vs 82%) and as specific as OB (89% vs 90%). We also found that the kappa FLC index value was not influenced by baseline MS clinical characteristics, by samples or analyzers differences, nor by steroid exposure at sampling reinforcing its interest as diagnostic biomarker.Finally, we evaluated whether the baseline value of the kappa FLC index was able to predict clinical relapses or new MRI lesions during follow-up, in patients presenting with clinically or radiologically isolated syndromes (CIS and RIS). Based on the retrospective study of 182 patients (146 CIS and 36 RIS), the kappa FLC index was able to predict new MRI lesions in CIS (AUC of 0.86 and 0.96 at 12 and 48 months respectively - Hazard ratio of 1.06 [1.04; 1.07], p<.0001), and in RIS (AUC of 0.84 and 0.64 at 12 and 24 months respectively - Hazard ratio of 1.08 [1.03; 1.13], p=.002), but also clinical relapse in CIS (AUC of 0.75 and 0.87 at 12 and 48 months respectively - Hazard ratio of 1.04 [1.01; 1.07], p=.007).Our results suggest that a kappa FLC CSF-restricted synthesis (kappa FLC index or IF) is sensitive and specific for MS diagnosis, and may predict clinical and MRI disease course in the earliest phases of the disease. Therefore we suggest adding kappa FLC biomarkers (whether it is kappa FLC index or IF) in the further revisions of MS diagnostic criteria